Idarubicin is an anti-cancer drug used in the treatment of leukemia. During the manufacturing process of Idarubicin, impurities may be formed which can affect the purity and potency of the drug. These impurities need to be identified, controlled and minimized to ensure the safety and efficacy of the drug. The most common impurities found in Idarubicin include 4-demethoxydaunorubicin, 4-demethoxydaunorubicinol, and daunorubicin.